[Sitosterol in familial hyperlipoproteinemia type II. A randomized double-blind cross-over study].
The effect of beta-sitosterol on the lipid and lipoprotein level was evaluated in a randomised double-blind cross-over trial in 24 patients with primary familial type II hyperlipoproteinaemia over a period of 16 weeks. All patients completed the trial, however 10 of them had to be excluded from the evaluation due to fluctuations of their body weight or unreliable drug intake. Sitosterol lowered the total cholesterol level by 12.5% (P less than 0.01) from 9.96 mmol/l (3.69 g/l) to 8.37 mmol/l (3.23 g/l). The LDL-cholesterol level was lowered by 19.5% (P less than 0.05). The sitosterol concentration in plasma was consistently lower than 0.3% of total cholesterol. No side effects or tachyphylaxis was observed in the course of the trial. A return to normal of an increased serum cholesterol level by a combination of a lipid lowering diet and sitosterol monotherapy was only achieved in one patient.
D000293:Adolescent; D000328:Adult; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000235:genetics*; D008077:Lipoproteins, LDL / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012855:Sitosterols / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*
D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010919:Placebos; D012855:Sitosterols; D002784:Cholesterol
Sitosterin bei familiärer Hyperlipoproteinämie Typ II. Eine randomisierte gekreuzte Doppelblindstudie